argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia GravisGlobeNewsWire • 11/16/23
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific SessionsGlobeNewsWire • 11/01/23
Argenx Comes Up With Big Sales Beat, Narrower-Than-Expected LossesInvestors Business Daily • 10/31/23
argenx Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 10/31/23
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023GlobeNewsWire • 10/24/23
Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million OfferingInvestors Business Daily • 09/27/23
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia GravisGlobeNewsWire • 09/21/23
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia GravisGlobeNewsWire • 09/15/23
argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business UpdateGlobeNewsWire • 07/27/23
Argenx Stock Rides 'Megabuster' Drug Excitement To 40% Gain Before EarningsInvestors Business Daily • 07/26/23
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023GlobeNewsWire • 07/20/23
argenx announces full exercise of underwriters' option to purchase additional ADSsGlobeNewsWire • 07/19/23
argenex SE (ARGX) Surges 27.8%: Is This an Indication of Further Gains?Zacks Investment Research • 07/18/23